Alphamab Oncology Toekomstige groei
Future criteriumcontroles 5/6
Alphamab Oncology is forecast to grow earnings and revenue by 70.1% and 39.4% per annum respectively. EPS is expected to grow by 70.1% per annum. Return on equity is forecast to be -11.3% in 3 years.
Belangrijke informatie
70.1%
Groei van de winst
70.1%
Groei van de winst per aandeel
| Biotechs winstgroei | 41.8% |
| Inkomstengroei | 39.4% |
| Toekomstig rendement op eigen vermogen | -11.3% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 01 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable
Sep 30
Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding
Jun 20Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up
May 06Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking
Mar 13Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price
Jan 17Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch
May 21Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts
Mar 01Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?
Oct 04Is Alphamab Oncology (HKG:9966) A Risky Investment?
May 21Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt
Oct 05Is Alphamab Oncology (HKG:9966) Using Too Much Debt?
May 05Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 720 | 201 | 243 | N/A | 3 |
| 12/31/2025 | 432 | -134 | -85 | N/A | 3 |
| 12/31/2024 | 338 | -103 | -55 | N/A | 3 |
| 6/30/2024 | 256 | -216 | -194 | -175 | N/A |
| 3/31/2024 | 237 | -213 | -217 | -189 | N/A |
| 12/31/2023 | 219 | -211 | -239 | -203 | N/A |
| 9/30/2023 | 234 | -214 | -277 | -215 | N/A |
| 6/30/2023 | 250 | -218 | -315 | -228 | N/A |
| 3/31/2023 | 208 | -272 | -372 | -264 | N/A |
| 12/31/2022 | 167 | -326 | -430 | -300 | N/A |
| 9/30/2022 | 183 | -309 | -423 | -275 | N/A |
| 6/30/2022 | 200 | -292 | -416 | -251 | N/A |
| 3/31/2022 | 173 | -352 | -447 | -286 | N/A |
| 12/31/2021 | 146 | -412 | -479 | -321 | N/A |
| 9/30/2021 | 73 | -502 | -499 | -368 | N/A |
| 6/30/2021 | N/A | -592 | -519 | -415 | N/A |
| 3/31/2021 | N/A | -510 | -478 | -381 | N/A |
| 12/31/2020 | N/A | -428 | -438 | -347 | N/A |
| 9/30/2020 | 1 | -652 | -422 | -305 | N/A |
| 6/30/2020 | 2 | -877 | -406 | -263 | N/A |
| 3/31/2020 | -1 | -851 | -423 | -261 | N/A |
| 12/31/2019 | 5 | -833 | -397 | -225 | N/A |
| 9/30/2019 | 3 | -495 | -347 | -201 | N/A |
| 6/30/2019 | 1 | -157 | -298 | -177 | N/A |
| 3/31/2019 | 6 | -176 | -207 | -113 | N/A |
| 12/31/2018 | -1 | -150 | -167 | -94 | N/A |
| 12/31/2017 | 1 | -33 | N/A | -65 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 9966 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Winst versus markt: 9966 is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: 9966 is expected to become profitable in the next 3 years.
Omzet versus markt: 9966's revenue (39.4% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).
Hoge groei-inkomsten: 9966's revenue (39.4% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: 9966 is forecast to be unprofitable in 3 years.